On November 12, 2020, Metagenomi, a next-generation gene editing company launched by UC Berkeley scientists in 2018, emerged from stealth mode and successfully completed a US$65 million Series A financing round. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures, and HOF Capital. Wilson Sonsini advised Metagenomi on patent matters related to the transaction and launch of the company.

Capital raised during this round will enable Metagenomi to accelerate the expansion of its gene editing systems for potential therapeutic use. In addition, Metagenomi will advance research and preclinical validation for its own pipeline. New hires will help sustain the growth Metagenomi has seen in 2020 and carry the company through further scientific advancements.

The Wilson Sonsini team that advised Metagenomi on patent matters related to the transaction and launch includes Ali Alemozafar, Michael Hostetler,  and Brandon Tavshanjian.

For more information, please see Metagenomi’s press release.